Stock 300436 FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Fujian Cosunter Pharmaceutical Co., Ltd.

Equities

300436

CNE100001YZ0

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 08/05/2024 BST 		5-day change 1st Jan Change
18.88 CNY +0.53% Intraday chart for Fujian Cosunter Pharmaceutical Co., Ltd. +5.24% -26.34%
04-19 Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Jiangsu Zhongxing Pharm Co., Ltd. cancelled the transaction announced on July 5, 2021 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jiangsu Zhongxing Pharm Co., Ltd. cancelled the transaction announced on July 5, 2021
CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) added to S&P Global BMI Index
CI
Fujian Cosunter Pharmaceutical Co., Ltd. agreed to acquire remaining 5.8333% stake in Jiangsu Zhongxing Pharm Co., Ltd. from Zhang Zhijun for CNY 10.6 million.
CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Cosunter Pharma Signs 14 Million Yuan Equipment Purchase Deal
MT
Fujian Cosunter Pharma's Unit Completes Clinical Trials on COVID-19 Drug
MT
Fujian Cosunter Pharma Gets Nod to Market Men's Drug
MT
Fujian Cosunter Pharma Completes Enrollment for COVID-19 Drug; Shares Drop 3%
MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Fujian Cosunter Pharma Unit Gets Drug Production License from Provincial Regulator
MT
Chinese Shares End Mixed; Cosunter Pharma Rallies 11% as COVID-19 Drug Seen More Effective Versus Pfizer's
MT
Fujian Cosunter Pharma Says COVID-19 Drug More Effective Than Pfizer’s Paxlovid; Shares Rally 14%
MT
Fujian Cosunter Pharma Selling 948 Million Yuan Shares to Fund New Drug Research Platform
MT
Fujian Cosunter Pharmaceutical Co., Ltd. announced that it expects to receive CNY 948 million in funding
CI
Fujian Cosunter Pharma Enrolls First Patient for Anti-COVID Drug Trial
MT
Fujian Cosunter’s Trial of Anti-COVID Tablets Shows Drug’s Safety; Shares Up 4%
MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300436 Stock
  4. News Fujian Cosunter Pharmaceutical Co., Ltd.